Katie Hill, MPH
she/her/hers
DownloadHi-Res Photo
Cards
Contact Info
Education
MPH
Milken Institute School of Public Health at George Washington University, Epidemiology (2022)
Milken Institute School of Public Health at George Washington University, Epidemiology (2022)
BA
University of Virginia, Biology and Interdisciplinary Studies (2018)
University of Virginia, Biology and Interdisciplinary Studies (2018)
About
Copy Link
Biography
Katherine (Katie) Hill is a PhD candidate in Epidemiology of Microbial Diseases working under the mentorship of Dr. Robert Heimer. She is also a Public Health Workforce Development Fellow with the Office of Public Health Practice. Her research interests include substance use, harm reduction, xylazine, kratom, sexual health and behavior, and improving the health of incarcerated individuals.
Last Updated on October 06, 2024.
Education & Training
- MPH
- Milken Institute School of Public Health at George Washington University, Epidemiology (2022)
- BA
- University of Virginia, Biology and Interdisciplinary Studies (2018)
Research
Copy Link
Overview
Medical Research Interests
Community-Based Participatory Research; Controlled Substances; Public Health Systems Research; Soft Tissue Injuries; Substance-Related Disorders; Veterinary Drugs
Public Health Interests
Health Equity, Disparities, Social Determinants and Justice; Community Health; Implementation Science; Mental Health; Sexually-Transmitted Infections; Stigma and Discrimination; Substance Use, Addiction
ORCID
0000-0002-6515-8701
Research at a Glance
Yale Co-Authors
Frequent collaborators of Katie Hill's published research.
Publications Timeline
A big-picture view of Katie Hill's research output by year.
Research Interests
Research topics Katie Hill is interested in exploring.
Kimberly Sue, MD, PhD
Robert Heimer, PhD
Emma Biegacki, MPH
Jenna L. Butner, MD, MPH, FASAM, AAHIVS
Benjamin Howell, MD, MPH, MHS
Lauretta Grau, PhD
24Publications
70Citations
Substance-Related Disorders
Publications
2026
Zeroing in on xylazine - a mixed methods study to explore correlates of reported xylazine use and educational gaps among people who use drugs
Hill K, Minahan-Rowley R, Biegacki E, Heimer R, Sue K. Zeroing in on xylazine - a mixed methods study to explore correlates of reported xylazine use and educational gaps among people who use drugs. Harm Reduction Journal 2026, 23: 88. PMID: 41933329, PMCID: PMC13173959, DOI: 10.1186/s12954-026-01437-7.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsThematic analysisSurvey participantsPurposive samplingSample of survey participantsLogistic regressionService use experiencesMixed methods studyMultiple logistic regressionTopic guideXylazine useIn-depth interviewsStigma-freeMethods studyService engagementVoices of peopleDescriptive statisticsHarm reductionEducational initiativesDemographic informationChi-squareEducational gapDrug useInterviewsT-testParticipantsAn Approach to Building a Strong Public Health Workforce: The Connecticut Public Health Fellowship Program.
Nappi S, Allen N, Hill K, Aviles E, Meise-Munns E, Petros M, Asada Y, Jarpe-Ratner E, Lane J, Pérez-Escamilla R. An Approach to Building a Strong Public Health Workforce: The Connecticut Public Health Fellowship Program. J Public Health Manag Pract 2026, 32: 34-43. PMID: 41260590, DOI: 10.1097/PHH.0000000000002275.Peer-Reviewed Original ResearchDiversification of Kratom in US Markets: Results from an Online Survey and Chemical Assay of Products.
Hill K, Henderson A, Sharma A, Kanumuri SRR, Mukhopadhyay S, Veltri C, Smith KE, McCurdy CR, Grundmann O. Diversification of Kratom in US Markets: Results from an Online Survey and Chemical Assay of Products. Subst Use Misuse 2026, 61: 237-246. PMID: 40853511, DOI: 10.1080/10826084.2025.2551707.Peer-Reviewed Original Research
2025
Clinically characterizing adults who use kava or kratom: Substance use disorder assessment challenges for increasingly popular botanical products.
Hill K, Boyer EW, Smith KE. Clinically characterizing adults who use kava or kratom: Substance use disorder assessment challenges for increasingly popular botanical products. Drug Alcohol Depend Rep 2025, 17: 100394. PMID: 41322679, DOI: 10.1016/j.dadr.2025.100394.Peer-Reviewed Original ResearchIn Support of a Public Health Approach to Drug Policy: Position Statement of AMERSA, Inc
Hill K, Rife-Pennington T, Zagorski C, Dunham K, Sue K, Davis C, Incze M. In Support of a Public Health Approach to Drug Policy: Position Statement of AMERSA, Inc. Substance Use & Addiction Journal 2025, 47: 309-315. PMID: 41199684, DOI: 10.1177/29767342251381162.Peer-Reviewed Original ResearchAltmetricConceptsDrug policyPublic health approachPunitive measuresPosition statementHealth approachHarm reduction servicesDrug-induced homicide lawsPublic health evidenceHarm reduction strategiesEvidence-based interventionsPunitive approachReduction servicesHarm reductionHomicide lawsSubstance useHealth evidencePolicyMultidisciplinary educationOverdose crisisUnited StatesLawHarmDrug supplyReduction strategiesCase studyTianeptine Products: Public Health Threat or Niche Substance use?
Smith KE, Hill K, Bergeria CL, Strickland JC. Tianeptine Products: Public Health Threat or Niche Substance use? J Psychoactive Drugs 2025, 1-11. PMID: 41084181, DOI: 10.1080/02791072.2025.2570939.Peer-Reviewed Original Research“Everybody’s Liking It”—Intentional Use of Xylazine in Fentanyl Among People Who Use Drugs
Hill K, Heimer R, Sue K. “Everybody’s Liking It”—Intentional Use of Xylazine in Fentanyl Among People Who Use Drugs. Substance Use & Misuse 2025, 61: 209-216. PMID: 40847818, DOI: 10.1080/10826084.2025.2549499.Peer-Reviewed Original ResearchCitationsAltmetricCommunity-Originated Research to Identify Access Gaps in Over-the-Counter Naloxone Availability in Connecticut Pharmacies.
Hill K, Canning P, Canning Z, Breen C, Evans L, Jenkins M, Nickel M, Plourd K, Heimer R. Community-Originated Research to Identify Access Gaps in Over-the-Counter Naloxone Availability in Connecticut Pharmacies. Harm Reduct J 2025, 22: 119. PMID: 40660265, DOI: 10.1186/s12954-025-01268-y.Peer-Reviewed Original ResearchDe facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing.
Hill K, Boyer EW, Grundmann O, Smith KE. De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing. Drug Alcohol Depend 2025, 272: 112701. PMID: 40373645, DOI: 10.1016/j.drugalcdep.2025.112701.Peer-Reviewed Original ResearchA composite vignette: xylazine, infectious complications and the importance of community-based drug checking services
John L, Flint N, Piccolo F, Hill K, Anderson M, Townsend B, Fletcher M, Altomare-Jarczyk C, Silvia K, Green T, Thamattoor D, Bessette J, Thakarar K. A composite vignette: xylazine, infectious complications and the importance of community-based drug checking services. Therapeutic Advances In Infectious Disease 2025, 12: 20499361251365090. PMID: 40822666, PMCID: PMC12357011, DOI: 10.1177/20499361251365090.Peer-Reviewed Original ResearchAltmetric
News
Copy Link
News
- May 23, 2025Source: CT Mirror
CT’s health commissioners should support overdose prevention centers
- April 07, 2025Source: Hartford Courant
Opinion: The need for overdose prevention centers in Connecticut
- August 20, 2024
Cause of Death After Prison Release Differs From General Population
- March 14, 2024Source: CT Mirror
For CT’s incarcerated, health care becomes an opportunity for punishment
Get In Touch
Copy Link
Contacts
Email